Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04546620
Title Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (REMoDL-A)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Hospital Southampton NHS Foundation Trust
Indications

B-cell lymphoma

diffuse large B-cell lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate

Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate

Age Groups: senior | child | adult
Covered Countries


No variant requirements are available.